AlphaYouFF
Schedule 13D filing
Fairmount Funds Management LLC disclosed a 10% stake in Spyre Therapeutics, Inc. (SYRE)
Fairmount Funds Management LLC reported owning 10% of Spyre Therapeutics, Inc. (SYRE) (10,185,961 shares) in a Schedule 13D filed Oct 9, 2026.
A 13D means the holder may push for changes at the company.
- Disclosed
- Oct 9, 2026
- Source
- Schedule 13D
More SYRE insider and Congress trades
From a public Schedule 13D, linked above. Not investment advice, and not a recommendation to buy or sell.